Spectrum Pharmaceuticals, Inc. Overview

State:California
Country:United States
Industry:Biotechnology and Drugs
Description:
Spectrum Pharmaceuticals, Inc. ( Spectrum) is a commercial stage biopharmaceutical company, engaged in developing and commercializing therapies with a focus primarily in the areas of hematology-oncology and urology. The Company has a fully developed commercial infrastructure that markets and sells two drugs in the United States, Zevalin and Fusilev. The Company has several drug candidates in development, which include apaziquone (EOquin), which is being studied in two large Phase III clinical trials for non-muscle invasive bladder cancer (NMIBC) under a strategic collaboration with Allergan; and belinostat, a drug partnered with TopoTarget A/S to jointly develop. Belinostat is being studied in multiple indications, including a Phase II registrational trial... (More)

Get Trial Access to OneSource

Company profiles, executive contacts, industry research, and news for sales, marketing and research professionals.

Business Information

Executive Profiles

Richard Charles, Alan David Dangour, Giusy Giacoppo, Alessandro Gollin, Paul Kiernan, George Kuo, Jean-Jacques Lambert, Ningfeng Li, John O'Brien, Laura Zaccaria

Company Lists

Disclaimer: While the OneSource Subscription Service maintains the freshest, most accurate data possible, this free site is refreshed on a periodic basis and may occasionally contain information that is not current. If you would like to alert us to a change, please email us, and we will take steps to make sure your update is included as soon as possible